"Preview" Icon

Diltiazem

Tiamate (diltiazem) is a small molecule pharmaceutical. Diltiazem was first approved as Tiamate on 1996-10-04. It is used to treat atrial fibrillation, atrial flutter, hypertension, myocardial infarction, and supraventricular tachycardia amongst others in the USA. The pharmaceutical is active against voltage-dependent L-type calcium channel subunit alpha-1S. In addition, it is known to target 5-hydroxytryptamine receptor 3A, Voltage-dependent L-type calcium channel subunit alpha-1F, potassium voltage-gated channel subfamily A member 5, potassium voltage-gated channel subfamily A member 7, voltage-dependent L-type calcium channel subunit alpha-1C, potassium voltage-gated channel subfamily A member 1, potassium voltage-gated channel subfamily C member 1, cyclic nucleotide-gated cation channel alpha-3, voltage-dependent L-type calcium channel subunit alpha-1D, cGMP-gated cation channel alpha-1, cyclic nucleotide-gated cation channel beta-3, cyclic nucleotide-gated olfactory channel, and potassium voltage-gated channel subfamily A member 2.

$4,995

Want to know more?
Schedule a demo or contact us for additional purchasing options.

Trade Name

Tiamate

Common Name

diltiazem

ChEMBL ID

CHEMBL23

Indication

atrial fibrillation, atrial flutter, hypertension, myocardial infarction, supraventricular tachycardia, variant angina pectoris

Drug Class

Calcium channel blockers (diltiazem type)

Image (chem structure or protein)

Diltiazem structure rendering

$4,995

Want to know more?
Schedule a demo or contact us for additional purchasing options.

Every Drug Dataset Includes...

Full Drug Information

Including:

Trade name (FDA, EMA)

Drug common name

Description

Classification

Drug class

Image (chemical or protein structure)

Protein Data Bank ID

Structure (InChI/SMILES or Protein Sequence)

CAS-ID

RxCUI

ChEMBL ID

ChEBI ID

PubChem CID

DrugBank ID

Indications

Including:

Agency approved indications

Phase 1 Indications

Phase 2 Indications

Phase 3 Indications

Phase 4 Indications

MeSH identifiers

Ontology identifiers

Target Information

Including:

Agency Approved Targets

Alternative Targets

Gene name

Gene synonyms

NCBI Gene ID

Protein name

Protein synonyms

Uniprot ID

Orthologs

Clinical Variant Information

Including:

ClinVar ID

Target mutation

Effect

Evaluation date

PharmGKB level

Clinical Trial Information

Including:

NCT ID

Trial Timeline

Results

Phase

Expanded Access

Official Title

Sponsor

Indications / Phase Indications

Study Type

Enrollment

Inclusion Criteria

Exclusion Criteria

Links to Clinical Trials

Reimbursement Codes

Including:

ICD-10

ATC

HCPCS

Safety Information

Including:

Black Box Warnings

Adverse Events

Adverse Reactions

Expedite Criteria

Trend Information

Including:

Top, trending, and new metadata terms in the following categories:

Disease or Syndrome

Pharmacological Substances

Biological Entities

Laboratory Procedures

Commercial Information

Including:

Company (FDA, EMA)

Approval Date (FDA, EMA)

Exclusivity

Patent Expiration

Generics and Biosimilars (FDA, EMA)

Drug Labels

Economic Information

Including:

Company

Annual revenue

Quarterly revenue

Global sales

US sales

Non-US sales

Full dataset compatible with-

SQL logo
SQL for web applications
<strong>R</strong> for statistical modeling
R for statistical modeling
Spotfire and tableau logos
Spotfire & Tableau for visualization
<strong>CSV</strong> export file format
CSV export file format
JSON logo
JSON export file format
XLSX logo
XLSX export file format

Continually updated information available as a yearly subscription for individual drug-of-interest.

$4,995

Schedule a demo to see what you get or contact us for additional or enterprise purchasing options.